Literature DB >> 28202224

The metastatic potential of renal tumors: Influence of histologic subtypes on definition of small renal masses, risk stratification, and future active surveillance protocols.

Michael Daugherty1, Dillon Sedaghatpour1, Oleg Shapiro1, Srinivas Vourganti1, Alexander Kutikov2, Gennady Bratslavsky3.   

Abstract

OBJECTIVE: The influence of histology in metastatic potential is often overlooked when discussing the management options of small renal masses (SRM), with size or growth rate often serving as the triggers for the intervention. We aim to re-examine the definition of a SRM by evaluating the metastatic potential of renal masses incorporating tumor size and histology to create metastatic risk tables.
MATERIALS AND METHODS: Surveillance Epidemiology and End Results (SEER)-18 registries database was queried for all cases of clear cell, papillary, and chromophobe renal cell carcinoma (RCC) diagnosed between 2004 and 2012. There were 55,478 cases identified that included 43,783, 8,587, and 3,208 cases of clear cell, papillary, and chromophobe, respectively. Tumors were stratified using 1-cm increments to determine the metastatic potential by calculating the metastatic rate at presentation for different size intervals in histologic categories.
RESULTS: For all 3 histologies, tumors measuring 5cm or less had a rate of metastatic RCC at presentation of less than 4%. The metastatic potential was highest for clear cell, followed by papillary and then chromophobe tumors. Setting a cutoff of no more than 3% for metastatic potential to be called a SRM, makes clear cell carcinoma and papillary carcinoma a SRM up to 4cm, whereas the chromophobe RCC would be considered a SRM up to 7cm.
CONCLUSION: Although clinical staging and tumor size have been the key determinants in decision-making of patients with solid renal tumors, the histology-specific risks of metastatic potential are different for each mass. The definition of a SRM should be based on the metastatic potential and not on tumor size alone. This information could be helpful for counseling and managing patients with SRMs as well as for modifying active surveillance protocols.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Histology; Renal biopsy; Renal cancer; Synchronous metastasis; Tumor size

Mesh:

Year:  2017        PMID: 28202224     DOI: 10.1016/j.urolonc.2016.11.009

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  9 in total

1.  Diagnostic test accuracy of ADC values for identification of clear cell renal cell carcinoma: systematic review and meta-analysis.

Authors:  Mickael Tordjman; Rahul Mali; Guillaume Madelin; Vinay Prabhu; Stella K Kang
Journal:  Eur Radiol       Date:  2020-03-06       Impact factor: 5.315

Review 2.  Current Management of Small Renal Masses, Including Patient Selection, Renal Tumor Biopsy, Active Surveillance, and Thermal Ablation.

Authors:  Alejandro Sanchez; Adam S Feldman; A Ari Hakimi
Journal:  J Clin Oncol       Date:  2018-10-29       Impact factor: 44.544

3.  The spinal distribution of metastatic renal cell carcinoma: Support for locoregional rather than arterial hematogenous mode of early bony dissemination.

Authors:  Kyrollis Attalla; Cihan Duzgol; Lily McLaughlin; Jessica Flynn; Irina Ostrovnaya; Paul Russo; Mark H Bilsky; A Ari Hakimi; Nelson S Moss
Journal:  Urol Oncol       Date:  2021-01-07       Impact factor: 3.498

4.  The impact of a multidisciplinary small renal mass clinic on patient treatment decisions.

Authors:  Danielle Earis; Chris Wall; Nicolette Sinclair; Trustin Domes; Kunal Jana
Journal:  Can Urol Assoc J       Date:  2022-02       Impact factor: 1.862

5.  Small renal masses in Latin-American population: characteristics and prognostic factors for survival, recurrence and metastasis - a multi-institutional study from LARCG database.

Authors:  Thiago Camelo Mourão; Diego Abreu; Gustavo F Carvalhal; Guillermo Gueglio; Walter H da Costa; Vinicius Fernando Calsavara; Luis Meza-Montoya; Rubén G Bengió; Carlos Scorticati; Ricardo Castillejos-Molina; Francisco Rodríguez-Covarrubias; Ana María Autran-Gómez; José Gadu Campos-Salcedo; Alejandro Nolazco; Carlos Ameri; Hamilton Zampolli; Raúl Langenhin; Diego Muguruza; Marcos Tobias Machado; Pablo Mingote; Jorge Clavijo; Lucas Nogueira; Omar Clark; Agustín R Rovegno; Fernando P Secin; Ricardo Decia; Gustavo C Guimarães; Sidney Glina; Oscar Rodríguez-Faba; Joan Palou; Stenio C Zequi
Journal:  BMC Urol       Date:  2020-07-02       Impact factor: 2.264

6.  Predictive Nomogram for Midterm to Long-Term Prognosis in Patients with Papillary Renal Cell Carcinoma Based on Data from the Surveillance, Epidemiology, and End Results (SEER) Program.

Authors:  Haosheng Wang; Xueliang Chen; Jianwu Zhao; Mingyang Kang; Rongpeng Dong; Kai Wang; Yang Qu
Journal:  Med Sci Monit       Date:  2020-06-22

7.  Initial Evaluation of Computer-Assisted Radiologic Assessment for Renal Mass Edge Detection as an Indication of Tumor Roughness to Predict Renal Cancer Subtypes.

Authors:  Rahul Rajendran; Kevan Iffrig; Deepak K Pruthi; Allison Wheeler; Brian Neuman; Dharam Kaushik; Ahmed M Mansour; Karen Panetta; Sos Agaian; Michael A Liss
Journal:  Adv Urol       Date:  2019-04-23

8.  Predictive Factors Affecting Metastasis of Small Renal Mass and Its Prognostic Analysis.

Authors:  Wei He; Zhuo Liu; Yu Tian; Yuxuan Li; Chuxiao Xu; Ruotao Xiao; Peng Hong; Shiying Tang; Liyuan Ge; Xun Zhao; Guodong Zhu; Hongxian Zhang; Cheng Liu; Lulin Ma
Journal:  Clin Med Insights Oncol       Date:  2022-02-17

9.  Development and Validation of a Nomogram to Predict Cancer-Specific Survival in Elderly Patients With Papillary Renal Cell Carcinoma.

Authors:  Chenghao Zhanghuang; Jinkui Wang; Zhigang Yao; Li Li; Yucheng Xie; Haoyu Tang; Kun Zhang; Chengchuang Wu; Zhen Yang; Bing Yan
Journal:  Front Public Health       Date:  2022-04-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.